Monitor the final pricing supplement for coupon rates and total offering size — the key variable is how much Teva saves on interest versus the called notes. The refinancing is credit-neutral to mildly positive for bonds but does not change the equity thesis. Watch for any subsequent 8-K confirming the closing and redemption execution.
Price Chart
Executive Summary
Teva is launching a multi-tranche debt offering of EUR and USD senior notes across five maturities (2032-2037), with proceeds intended to fund the conditional redemption of up to ~$4.5B in higher-coupon notes (6.750% 2028s, 7.875% 2029s, 7.375% 2029s, plus portions of 4.750% 2027s and 4.375% 2030s). This is a liability management refinancing that reduces near-term debt costs and extends maturities, but the offering size and final coupon rates are undisclosed in this preliminary filing. The transaction is credit-positive for bondholders (removing expensive debt) but neutral for equity holders as it does not change the fundamental business outlook or leverage trajectory beyond the refinancing math.
Key Facts
- Teva is offering five series of senior unsecured notes: EUR 2033s, EUR 2036s, USD 2032s, USD 2034s, and USD 2037s.
- Proceeds will fund conditional redemptions of up to $1.25B of 6.750% 2028 USD notes, $398M of 7.875% 2029 USD notes, €758M of 7.375% 2029 EUR notes, $450M of 4.750% 2027 USD notes, and €1.25B of 4.375% 2030 EUR notes.
- The offering is conditioned on the redemptions, but the redemptions are not conditioned on the offering.
- Teva had $16.65B of senior unsecured indebtedness outstanding as of June 30, 2026, and no secured debt.
- LTM net revenues were $17.315B and LTM Adjusted EBITDA was $4.56B as of June 30, 2026.
- The filing is preliminary — coupon rates, offering sizes, and final pricing are all placeholder values.
- The underwriters include BNP Paribas, Citigroup, Goldman Sachs, J.P. Morgan, BofA, HSBC, Mizuho, and others.
Financial Impact
Refinancing of up to ~$4.5B in higher-coupon debt with new notes at current market yields; exact interest savings depend on final pricing, which is undisclosed.
Risk Factors
- Offering size and coupon rates are undisclosed — actual terms may differ materially from market expectations.
- The offering is not conditioned on the redemptions, creating execution risk if market conditions shift.
- Teva's LTM net income attributable to Teva was only $706M, and the company reported a net loss of $207M in H1 2026, indicating thin earnings coverage of the enlarged debt base.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-384343 |
| Document: 0001193125-26-384343-index-headers.html | 0001193125-26-384343 |
| Document: 0001193125-26-384343-index.html | 0001193125-26-384343 |
| Document: 0001193125-26-384343.txt | 0001193125-26-384343 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $36.35 $39.19 | ▲ +7.81% | ▲ +8.31% | $39.29 (+8.09%) |
Sep 8, 2026 24d ago | 424B5 | $36.76 $39.25 | ▲ +6.77% | ▲ +7.89% | $39.29 (+6.88%) |
Sep 2, 2026 4w ago | Court Ruling | $37.49 $36.35 | ▼ −3.04% | ▼ −2.08% | $39.29 (+4.80%) |
Aug 28, 2026 5w ago | Press Release | $36.44 $36.36 | ▼ −0.22% | ▼ −0.33% | $39.29 (+7.82%) |
Aug 25, 2026 5w ago | Court Ruling | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.29 (+3.12%) |
Aug 25, 2026 5w ago | Insider Cluster | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.29 (+3.12%) |
Aug 10, 2026 7w ago | Insider Cluster | $36.14 $36.46 | ▲ +0.89% | ▲ +0.93% | $39.29 (+8.72%) |
Aug 5, 2026 8w ago | Insider Cluster | $34.81 $36.45 | ▲ +4.70% | ▲ +3.49% | $39.29 (+12.87%) |
Jul 31, 2026 9w ago | Court Ruling | $35.01 $35.36 | ▲ +1.00% | ▼ −2.51% | $39.29 (+12.23%) |
Jul 29, 2026 9w ago | 8-K | $34.71 $34.72 | ▲ +0.03% | ▼ −5.50% | $39.29 (+13.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access